Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00685880PMID 8462127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sensitization of human melanoma cells to melphalan cytotoxicity by Adriamycin and carmustine

  2005cited by this paper
• The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma

  2004cited by this paper
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Carcinoma of the prostate.

  1991cited by this paper
• The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells.

  1991influential reference
• Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid.

  1991cited by this paper
• Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells.

  1990cited by this paper
• Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.

  1990cited by this paper
• Cancer statistics, 1990

  1990cited by this paper
• Elimination of malignant clonogenic breast cancer cells from human bone marrow.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper
• Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.

  1989cited by this paper
• Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.

  1989cited by this paper
• Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.

  1989cited by this paper
• Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.

  1989cited by this paper
• Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.

  1989cited by this paper
• Is There a Place for Chemotherapy in Advanced Prostatic Cancer?

  1988cited by this paper
• Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines.

  1988cited by this paper
• Evidence that glutathione may determine the differential cell-cycle phase toxicity of a platinum (IV) antitumor agent.

  1988cited by this paper
• Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.

  1988cited by this paper
• Melphalan-induced DNA cross-linking in human melanoma cells and phytohaemagglutinin-stimulated lymphocytes in relation to intracellular drug content and cellular levels of glutathione.

  1987cited by this paper
• Multidrug resistance in ovarian cancer

  1987cited by this paper
• Chemotherapy of urologic malignancies.

  1985cited by this paper
• Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation.

  1985cited by this paper
• Determination of glutathione and glutathione disulfide in biological samples.

  1985cited by this paper
• Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

  1985cited by this paper
• Phase II trial of etoposide in advanced prostate cancer.

  1984cited by this paper
• Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.

  1984cited by this paper
• Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.

  1983cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.

  1982cited by this paper
• Prostatic carcinoma.

  1979cited by this paper
• Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine).

  1979cited by this paper
• Kinetics of intravenous melphalan

  1979cited by this paper
• Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

  1978cited by this paper
• Melphalan in advanced prostatic cancer: a pilot study.

  1977cited by this paper
• The chemotherapy of urologic cancer

  1975cited by this paper
• Phase II evaluation of adriamycin in human neoplasia

  1973cited by this paper
• [Prostatic carcinoma].

  1966cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Design Strategies and Applications of ROS-Responsive Phenylborate Ester-Based Nanomedicine.

  2020cites this paper
• Reactive oxygen species‐responsive nanoprodrug with quinone methides‐mediated GSH depletion for improved chlorambucil breast cancers therapy

  2018cites this paper
• Modulation of cell death in human colorectal and breast cancer cells through a manganese chelate by involving GSH with intracellular p53 status

  2017cites this paper
• Selective induction of apoptosis in various cancer cells irrespective of drug sensitivity through a copper chelate, copper N-(2 hydroxy acetophenone) glycinate: crucial involvement of glutathione

  2013cites this paper
• Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

  2006cites this paper
• Scintigraphic images of breast cancer with Tc-99m cysteine.

  2006cites this paper
• Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells

  2005cites this paper
• The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts

  2004cites this paper
• Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment

  2004cites this paper
• Changes in endogenous tissue glutathione level in relation to murine ascites tumor growth and the anticancer activity of cisplatin.

  2003cites this paper
• Priming prostate carcinoma cells for increased apoptosis is associated with up‐regulation of the caspases

  2001cites this paper
• Chemical modulation of chemotherapy resistance in cultured oesophageal carcinoma cells.

  2000cites this paper
• Thiol‐mediated apoptosis in prostate carcinoma cells

  2000cites this paper
• A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin.

  1999cites this paper
• Gamma-glutamyl transpeptidase immunoreactivity in benign and malignant breast tissue

  1997cites this paper
• Nitric oxide enhancement of melphalan-induced cytotoxicity.

  1997cites this paper
• Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer

  1997cites this paper
• Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues.

  1996cites this paper
• Hydroxyapatite beads containing Doxorubicin hydrochloride (dox) and buthionine sulfoximine (bso) - a new anticancer drug design for local treatment with multiple-drugs.

  1995cites this paper
• Enhancement of melphalan toxicity by octanol in ovarian adenocarcinoma cell lines: effects of altered cell-cell communication, glutathione levels, and plasma membrane fluidity.

  1995cites this paper
• Glutathione concentration in oral cancer tissues.

  1994cites this paper